Studies have shown that ridaforolimus selectively and potently inhibits mTOR function and proliferative activity in different human tumor cell lines in vitro and tumor xenograft models in vivo, and has synergistic activity when combined with other anticancer agents, such as doxorubicin and carboplatin/paclitaxel [16, 17]. The gene discussed is MTOR; the disease is neoplasm.